Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)
April 18, 2023 02:55 PM EDT
Pharma

J&J sales near $25B for Q1, with sol­id on­col­o­gy, im­munol­o­gy gains

Beth Snyder Bulik

Senior Editor

John­son & John­son tout­ed gains in its phar­ma­ceu­ti­cal busi­ness that were dri­ven by on­col­o­gy and im­munol­o­gy drugs, but it was un­ex­pect­ed gains on Covid-19 vac­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times